What is William Blair’s Estimate for CVRx FY2026 Earnings?

CVRx, Inc. (NASDAQ:CVRX) – Equities research analysts at William Blair issued their FY2026 earnings per share estimates for shares of CVRx in a research note issued on Friday, December 13th. William Blair analyst M. Andrew forecasts that the company will post earnings per share of ($1.91) for the year. The consensus estimate for CVRx’s current full-year earnings is ($2.62) per share.

Several other equities analysts also recently issued reports on the stock. Craig Hallum increased their price objective on shares of CVRx from $15.00 to $20.00 and gave the company a “buy” rating in a report on Monday, November 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $14.00 price objective on shares of CVRx in a report on Wednesday, October 23rd. Lake Street Capital boosted their price objective on CVRx from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Piper Sandler restated an “overweight” rating and issued a $16.00 target price (up previously from $13.00) on shares of CVRx in a research report on Wednesday, October 30th. Finally, Canaccord Genuity Group boosted their price target on CVRx from $17.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $16.67.

CVRx Price Performance

CVRx stock opened at $13.16 on Monday. The stock has a market capitalization of $319.31 million, a P/E ratio of -4.87 and a beta of 1.20. The company’s fifty day moving average price is $12.80 and its 200 day moving average price is $10.54. The company has a debt-to-equity ratio of 0.76, a quick ratio of 10.23 and a current ratio of 11.32. CVRx has a 1 year low of $6.40 and a 1 year high of $33.13.

CVRx (NASDAQ:CVRX) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.12). The business had revenue of $13.37 million during the quarter, compared to analyst estimates of $13.28 million. CVRx had a negative net margin of 123.75% and a negative return on equity of 89.06%. During the same period in the previous year, the business posted ($0.43) earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in shares of CVRx in the third quarter valued at approximately $108,000. XTX Topco Ltd purchased a new stake in CVRx in the 3rd quarter valued at $150,000. Jane Street Group LLC increased its stake in shares of CVRx by 36.1% in the 3rd quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock worth $168,000 after acquiring an additional 5,053 shares during the last quarter. Barclays PLC increased its stake in shares of CVRx by 312.5% in the 3rd quarter. Barclays PLC now owns 19,067 shares of the company’s stock worth $169,000 after acquiring an additional 14,445 shares during the last quarter. Finally, Centiva Capital LP purchased a new position in shares of CVRx during the 3rd quarter worth $178,000. 75.27% of the stock is owned by hedge funds and other institutional investors.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.